Company intelligence / Profile preview

Hangzhou Chengzhe Biopharmaceutical

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Hangzhou Chengzhe Biopharmaceutical Co., Ltd. is a pharmaceutical research and development company based in Hangzhou, China. Founded in December 2022, the company operates as a wholly-owned subsidiary of Hangzhou Xinnuohua Pharmaceutical Co., Ltd., which is ultimately owned by the publicly traded Ningbo Menovo Pharmaceutical Co., Ltd. Hangzhou Chengzhe Biopharmaceutical specializes in the technical development, optimization, and transfer of chemical drug formulations. The company utilizes advanced drug delivery platforms, including sustained-release and pellet technologies, to support the broader group's generic and specialty drug pipeline. Through its R&D activities, it aims to enhance manufacturing efficiency and product quality for small molecule therapeutics.

Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hangzhou Chengzhe Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Chengzhe Biopharmaceutical.

Explore the full profile